Literature DB >> 15531597

Emergence of invasive erythromycin-resistant Streptococcus pneumoniae strains in Portugal: contribution and phylogenetic relatedness of serotype 14.

Ricardo Dias1, Manuela Caniça.   

Abstract

OBJECTIVES: To study the phenotype and phylogenetic relatedness of invasive Streptococcus pneumoniae strains isolated in Portugal.
METHODS: A total of 614 invasive S. pneumoniae strains, isolated in Portugal from 1999 to the first 6 months of 2002, were characterized using serotyping and antimicrobial susceptibility testing. National outpatient sale data for macrolides were compared with erythromycin resistance. We investigated the main clonal lineages from erythromycin-resistant strains of serotype 14 by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST).
RESULTS: The emergence of erythromycin-resistant strains correlated well with the usage of azithromycin in Portugal during the period of the study (r=0.900, P=0.001). Serotype 14 made the largest contribution to this emergence. We found two clonal complexes (CC) among erythromycin-resistant strains: CC1 was formed by three sequence types (ST), ST156, ST143 and ST1042, and CC2 by ST15 and ST9. All STs described, except ST1042, are putative founders of clonal groups or subgroups from serotype 14 as defined in the pneumococcal MLST database.
CONCLUSIONS: This study suggests that macrolides usage is an important factor enhancing the spread of invasive erythromycin-resistant S. pneumoniae clones in Portugal. The study also makes a contribution to the understanding of spread of erythromycin-resistant clones in an international context.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531597     DOI: 10.1093/jac/dkh469

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

Review 1.  Macrolide-resistant Streptococcus pneumoniae: clinical implications for the empiric treatment of community-acquired respiratory tract infections.

Authors:  Stephen Brunton; Paul Iannini
Journal:  MedGenMed       Date:  2005-12-07

2.  Increase of the M phenotype among erythromycin-resistant Streptococcus pneumoniae isolates from Spain related to the serotype 14 variant of the Spain9V-3 clone.

Authors:  C Ardanuy; A Fenoll; S Berrón; L Calatayud; J Liñares
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period.

Authors:  Ricardo Dias; Deolinda Louro; Manuela Caniça
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Trends in resistance to penicillin and erythromycin of invasive pneumococci in Portugal.

Authors:  R Dias; M Caniça
Journal:  Epidemiol Infect       Date:  2007-08-16       Impact factor: 2.451

5.  Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006.

Authors:  Lotta Siira; Merja Rantala; Jari Jalava; Antti J Hakanen; Pentti Huovinen; Tarja Kaijalainen; Outi Lyytikäinen; Anni Virolainen
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

6.  Azithromycin use in paediatrics: A practical overview.

Authors:  Philippe Ovetchkine; Michael J Rieder
Journal:  Paediatr Child Health       Date:  2013-06       Impact factor: 2.253

7.  Seasonality of antibiotic-resistant streptococcus pneumoniae that causes acute otitis media: a clue for an antibiotic-restriction policy?

Authors:  Ron Dagan; Galia Barkai; Noga Givon-Lavi; Amir Z Sharf; Daniel Vardy; Ted Cohen; Marc Lipsitch; David Greenberg
Journal:  J Infect Dis       Date:  2008-04-15       Impact factor: 5.226

8.  Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.

Authors:  Xiaoping Xu; Lin Cai; Meng Xiao; Fanrong Kong; Shahin Oftadeh; Fei Zhou; Gwendolyn L Gilbert
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

Review 9.  Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia.

Authors:  Steven D Brown
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

10.  Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan.

Authors:  Rie Isozumi; Yutaka Ito; Tadashi Ishida; Makoto Osawa; Toyohiro Hirai; Isao Ito; Ko Maniwa; Michio Hayashi; Hitoshi Kagioka; Masataka Hirabayashi; Koichi Onari; Hiromi Tomioka; Keisuke Tomii; Iwao Gohma; Seiichiro Imai; Shunji Takakura; Yoshitsugu Iinuma; Satoshi Ichiyama; Michiaki Mishima
Journal:  J Clin Microbiol       Date:  2007-03-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.